A groundbreaking discovery by a collaborative team of scientists from the University of Colorado Boulder, Stanford University, and Baylor University…
Read More
Salk Institute Researchers Identify BCL6 Protein as Key to Preventing Muscle Loss During GLP-1 Weight Management and Aging
The rise of glucagon-like peptide-1 (GLP-1) receptor agonists has fundamentally transformed the landscape of metabolic medicine, offering unprecedented efficacy in…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its investigational weight loss treatment, CagriSema,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, announced a significant advancement in its weight management pipeline with…
Read More
